DE3025223A1 - Pharmazeutische zubereitungen auf der grundlage von efeuextrakten und verfahren zu ihrer herstellung - Google Patents
Pharmazeutische zubereitungen auf der grundlage von efeuextrakten und verfahren zu ihrer herstellungInfo
- Publication number
- DE3025223A1 DE3025223A1 DE19803025223 DE3025223A DE3025223A1 DE 3025223 A1 DE3025223 A1 DE 3025223A1 DE 19803025223 DE19803025223 DE 19803025223 DE 3025223 A DE3025223 A DE 3025223A DE 3025223 A1 DE3025223 A1 DE 3025223A1
- Authority
- DE
- Germany
- Prior art keywords
- hederasaponin
- extract
- pharmaceutical preparations
- ivy
- hederin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000284 extract Substances 0.000 title claims description 63
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 14
- 238000000034 method Methods 0.000 title claims description 11
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 48
- RYHDIBJJJRNDSX-MCGLQMIESA-N Hederacoside C Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@H](OC(=O)[C@@]34[C@@H](CC(C)(C)CC3)C=3[C@@]([C@]5(C)CC[C@H]6[C@](C)(CO)[C@@H](O[C@H]7[C@@H]([C@@H](O)[C@@H](O)CO7)O[C@H]7[C@@H]([C@H](O)[C@@H](O)[C@H](C)O7)O)CC[C@]6(C)[C@H]5CC=3)(C)CC4)O2)O)[C@H](O)[C@H]1O RYHDIBJJJRNDSX-MCGLQMIESA-N 0.000 claims description 33
- MLWBUURUTWPMOO-UHFFFAOYSA-N Hederasaponin C Natural products CC1OC(OC2C(O)COC(OC3CCC4(C)C(CCC5(C)C4CC=C6C7CC(C)(C)CCC7(CCC56C)C(=O)OC8OC(COC9OC(CO)C(OC%10OC(C)C(O)C(O)C%10O)C(O)C9O)C(O)C(O)C8O)C3(C)CO)C2O)C(O)C(O)C1O MLWBUURUTWPMOO-UHFFFAOYSA-N 0.000 claims description 33
- RYHDIBJJJRNDSX-UHFFFAOYSA-N kalopanax-saponin B Natural products OC1C(O)C(O)C(C)OC1OC1C(CO)OC(OCC2C(C(O)C(O)C(OC(=O)C34C(CC(C)(C)CC3)C=3C(C5(C)CCC6C(C)(CO)C(OC7C(C(O)C(O)CO7)OC7C(C(O)C(O)C(C)O7)O)CCC6(C)C5CC=3)(C)CC4)O2)O)C(O)C1O RYHDIBJJJRNDSX-UHFFFAOYSA-N 0.000 claims description 33
- 241000208341 Hedera Species 0.000 claims description 21
- 239000000047 product Substances 0.000 claims description 20
- 230000009194 climbing Effects 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 12
- 230000000843 anti-fungal effect Effects 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 7
- 238000007127 saponification reaction Methods 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 230000002141 anti-parasite Effects 0.000 claims description 6
- 229930182490 saponin Natural products 0.000 claims description 6
- 150000007949 saponins Chemical class 0.000 claims description 6
- 230000000507 anthelmentic effect Effects 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 5
- 239000003096 antiparasitic agent Substances 0.000 claims description 4
- 229930185042 hederasaponin Natural products 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000011877 solvent mixture Substances 0.000 claims description 2
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- KEOITPILCOILGM-LLJOFIFVSA-N kalopanaxsaponin A Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(CC[C@]6(CCC(C)(C)C[C@H]6C5=CC4)C(O)=O)C)(C)CC3)(C)CC2)(C)CO)OC[C@H](O)[C@@H]1O KEOITPILCOILGM-LLJOFIFVSA-N 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 15
- PXOYOCNNSUAQNS-AGNJHWRGSA-N alantolactone Chemical compound C1[C@H]2OC(=O)C(=C)[C@H]2C=C2[C@@H](C)CCC[C@@]21C PXOYOCNNSUAQNS-AGNJHWRGSA-N 0.000 description 11
- 238000011282 treatment Methods 0.000 description 10
- 241000242711 Fasciola hepatica Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 238000011835 investigation Methods 0.000 description 8
- 244000045947 parasite Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- TUFPZQHDPZYIEX-UHFFFAOYSA-N alpha-Santonin Natural products C1CC2(C)C=CC(=O)C=C2C2C1C(C)C(=O)O2 TUFPZQHDPZYIEX-UHFFFAOYSA-N 0.000 description 7
- 230000008034 disappearance Effects 0.000 description 7
- 229940074353 santonin Drugs 0.000 description 7
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241001494479 Pecora Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 206010000269 abscess Diseases 0.000 description 6
- XJHDMGJURBVLLE-BOCCBSBMSA-N alpha-santonin Chemical compound C([C@]1(C)CC2)=CC(=O)C(C)=C1[C@@H]1[C@@H]2[C@H](C)C(=O)O1 XJHDMGJURBVLLE-BOCCBSBMSA-N 0.000 description 6
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 6
- 229960003942 amphotericin b Drugs 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- 208000006275 fascioliasis Diseases 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 235000017709 saponins Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- MQFLXLMNOHHPTC-UHFFFAOYSA-N 1-isothiocyanato-9-(methylsulfinyl)nonane Chemical compound CS(=O)CCCCCCCCCN=C=S MQFLXLMNOHHPTC-UHFFFAOYSA-N 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001480043 Arthrodermataceae Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 241000577452 Dicrocoelium Species 0.000 description 3
- 240000008669 Hedera helix Species 0.000 description 3
- 101150029182 Hmmr gene Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000037304 dermatophytes Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000224489 Amoeba Species 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000869417 Trematodes Species 0.000 description 2
- 241000224526 Trichomonas Species 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960000901 mepacrine Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- SWDXALWLRYIJHK-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;piperazine Chemical compound C1CNCCN1.OC(=O)CC(O)(C(O)=O)CC(O)=O SWDXALWLRYIJHK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000404582 Hymenolepis <angiosperm> Species 0.000 description 1
- 241001464384 Hymenolepis nana Species 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000893980 Microsporum canis Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010042343 Subcutaneous abscess Diseases 0.000 description 1
- 241000975692 Syphacia obvelata Species 0.000 description 1
- 241000244155 Taenia Species 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical group 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- RIOXQFHNBCKOKP-UHFFFAOYSA-N benomyl Chemical compound C1=CC=C2N(C(=O)NCCCC)C(NC(=O)OC)=NC2=C1 RIOXQFHNBCKOKP-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000001069 nematicidal effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 229960000718 piperazine citrate Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/256—Polyterpene radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7917451A FR2460136B1 (fr) | 1979-07-05 | 1979-07-05 | Compositions pharmaceutiques contenant des extraits de lierre grimpant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3025223A1 true DE3025223A1 (de) | 1981-01-08 |
Family
ID=9227547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19803025223 Withdrawn DE3025223A1 (de) | 1979-07-05 | 1980-07-03 | Pharmazeutische zubereitungen auf der grundlage von efeuextrakten und verfahren zu ihrer herstellung |
Country Status (13)
| Country | Link |
|---|---|
| AT (1) | AT369264B (enExample) |
| BE (1) | BE884190A (enExample) |
| CH (1) | CH647787A5 (enExample) |
| DE (1) | DE3025223A1 (enExample) |
| ES (1) | ES493118A0 (enExample) |
| FR (1) | FR2460136B1 (enExample) |
| GB (1) | GB2051575B (enExample) |
| GR (1) | GR69637B (enExample) |
| IE (1) | IE50062B1 (enExample) |
| IT (1) | IT1132510B (enExample) |
| LU (1) | LU82583A1 (enExample) |
| NL (1) | NL8003871A (enExample) |
| PT (1) | PT71495A (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4010042A1 (de) * | 1990-03-29 | 1991-10-24 | Cassella Ag | Verwendung von efeu zur topischen behandlung vermehrter schuppenbildung der behaarten und unbehaarten haut sowie der psoriasis |
| DE10345343A1 (de) * | 2003-09-19 | 2005-04-14 | Engelhard Arzneimittel Gmbh & Co. Kg | Verfahren zur Herstellung eines Extrakts aus Efeublättern und nach diesem Verfahren hergestellter Extrakt |
| DE10345342A1 (de) * | 2003-09-19 | 2005-04-28 | Engelhard Arzneimittel Gmbh | Verfahren zur Herstellung eines lagerstabilen Extraktes aus Efeublättern, sowie ein nach diesem Verfahren hergestellter Extrakt |
| US20110003022A1 (en) * | 2007-12-21 | 2011-01-06 | Mark Stephen Baird | Composition and Method |
| WO2015032922A1 (en) * | 2013-09-06 | 2015-03-12 | Mars, Incorporated | Oral anti-parasitic composition |
| CN114805466A (zh) * | 2022-04-15 | 2022-07-29 | 湖南朗林生物资源股份有限公司 | 一种常春藤提取物的制备方法 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1195849B (it) * | 1986-07-01 | 1988-10-27 | Sigma Tau Ind Farmaceuti | Saponine triterpeniche ad attivita' antiinfiammatoria,mucolitica ed antiedemigena,procedimento per il loro ottenimento e composizioni farmaceutiche che li comprendono |
| WO2004089357A2 (en) * | 2003-04-02 | 2004-10-21 | Regents Of The University Of Minnesota | Anti-fungal formulation of triterpene and essential oil |
| DE10335173A1 (de) * | 2003-07-30 | 2005-03-03 | Mirjana Kiener | Mittel zur Vergrösserung der weiblichen Brust |
| EP3939596A1 (en) * | 2020-07-14 | 2022-01-19 | Bimeda Animal Health Limited | A composition for treating helminth infestation in a mammal |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR6330E (fr) * | 1905-06-14 | 1906-10-13 | Petrus Johannes Portman | Dispositif automatique avec appareil de controle pour la sécurité de la circulation des chemins de fer |
| BE670523A (enExample) * | 1964-10-09 | |||
| FR6218M (enExample) * | 1967-05-24 | 1968-07-29 | ||
| FR2233071A1 (en) * | 1973-06-14 | 1975-01-10 | Prod Hyg Laboratoires | Flavones and saponins extracted from ivy - by solid-liquid extraction of undesirables followed by alcohol extraction |
-
1979
- 1979-07-05 FR FR7917451A patent/FR2460136B1/fr not_active Expired
-
1980
- 1980-07-03 DE DE19803025223 patent/DE3025223A1/de not_active Withdrawn
- 1980-07-04 AT AT0350580A patent/AT369264B/de not_active IP Right Cessation
- 1980-07-04 GR GR62377A patent/GR69637B/el unknown
- 1980-07-04 LU LU82583A patent/LU82583A1/fr unknown
- 1980-07-04 ES ES493118A patent/ES493118A0/es active Granted
- 1980-07-04 IE IE1393/80A patent/IE50062B1/en unknown
- 1980-07-04 NL NL8003871A patent/NL8003871A/nl not_active Application Discontinuation
- 1980-07-04 CH CH5153/80A patent/CH647787A5/fr not_active IP Right Cessation
- 1980-07-04 GB GB8021943A patent/GB2051575B/en not_active Expired
- 1980-07-04 PT PT71495A patent/PT71495A/pt unknown
- 1980-07-04 IT IT23262/80A patent/IT1132510B/it active
- 1980-07-04 BE BE0/201310A patent/BE884190A/fr not_active IP Right Cessation
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4010042A1 (de) * | 1990-03-29 | 1991-10-24 | Cassella Ag | Verwendung von efeu zur topischen behandlung vermehrter schuppenbildung der behaarten und unbehaarten haut sowie der psoriasis |
| DE10345343A1 (de) * | 2003-09-19 | 2005-04-14 | Engelhard Arzneimittel Gmbh & Co. Kg | Verfahren zur Herstellung eines Extrakts aus Efeublättern und nach diesem Verfahren hergestellter Extrakt |
| DE10345342A1 (de) * | 2003-09-19 | 2005-04-28 | Engelhard Arzneimittel Gmbh | Verfahren zur Herstellung eines lagerstabilen Extraktes aus Efeublättern, sowie ein nach diesem Verfahren hergestellter Extrakt |
| US7943184B2 (en) | 2003-09-19 | 2011-05-17 | Engelhard Arzneimittel Gmbh & Co. Kg | Process for preparing an extract from ivy leaves |
| US20110003022A1 (en) * | 2007-12-21 | 2011-01-06 | Mark Stephen Baird | Composition and Method |
| WO2015032922A1 (en) * | 2013-09-06 | 2015-03-12 | Mars, Incorporated | Oral anti-parasitic composition |
| AU2014317025B2 (en) * | 2013-09-06 | 2019-12-05 | Mars, Incorporated | Oral anti-parasitic composition |
| AU2020201643B2 (en) * | 2013-09-06 | 2022-03-17 | Mars, Incorporated | Oral anti-parasitic composition |
| US11497785B2 (en) | 2013-09-06 | 2022-11-15 | Mars, Incorporated | Oral anti-parasitic composition |
| CN114805466A (zh) * | 2022-04-15 | 2022-07-29 | 湖南朗林生物资源股份有限公司 | 一种常春藤提取物的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES8103974A1 (es) | 1981-04-01 |
| FR2460136A1 (fr) | 1981-01-23 |
| LU82583A1 (fr) | 1980-10-08 |
| PT71495A (fr) | 1980-08-01 |
| CH647787A5 (fr) | 1985-02-15 |
| IT1132510B (it) | 1986-07-02 |
| FR2460136B1 (fr) | 1986-01-10 |
| IE50062B1 (en) | 1986-02-05 |
| GB2051575B (en) | 1984-01-18 |
| IE801393L (en) | 1981-01-05 |
| BE884190A (fr) | 1981-01-05 |
| NL8003871A (nl) | 1981-01-07 |
| ES493118A0 (es) | 1981-04-01 |
| IT8023262A0 (it) | 1980-07-04 |
| AT369264B (de) | 1982-12-27 |
| GR69637B (enExample) | 1982-07-06 |
| ATA350580A (de) | 1982-05-15 |
| GB2051575A (en) | 1981-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2557784C2 (de) | Forskolin, Verfahren zu dessen Gewinnung und diese Verbindung enthaltende pharmazeutische Präparate | |
| DE3611194A1 (de) | Cancerostatisches mittel | |
| DE10128266A1 (de) | Verfahren zur Herstellung eines Extrakts mit starker Antiinflammations-Antiblutplättchenaggregations- und Antifungi-Aktivität aus Zingiber officinale und pharmazeutische Zusammensetzungen, die diesen Extrakt enthalten | |
| DE2640275A1 (de) | Pharmakologisch wirksame substanz aus labiaten | |
| DE3025223A1 (de) | Pharmazeutische zubereitungen auf der grundlage von efeuextrakten und verfahren zu ihrer herstellung | |
| EP0004680B1 (de) | Nonatetraensäure-Derivat und pharmazeutische Kompositionen | |
| CH644845A5 (de) | N-(4-acyloxyphenyl)-all-trans-retinsaeureamide. | |
| DE2801186A1 (de) | Pflanzlicher extrakt aus chrysantellum-arten, verfahren zu seiner herstellung sowie den extrakt enthaltende arzneimittel | |
| DE3109335A1 (de) | Die neue, physiologisch wirksame substanz ebelacton und verfahren zur herstellung derselben | |
| DE2347576C2 (de) | Bruceantin und diese Verbindung enthaltende antileukämische Mittel | |
| DE1811518B2 (de) | Daunorubicinderivale, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
| DE3031788A1 (de) | Verwendung von sesquiterverbindungen zur herstellung von arzneimitteln zur prophylaxe und therapie von haepatitis | |
| DE69213886T2 (de) | Pflanzliches antineoplastisches chemotherapeutikum, mit hoher selektivitaet und sehr reduzierter toxizitaet, und verfahren zur herstellung | |
| DE2706156C3 (de) | N,N,N-Trimethylderivate amphoterer, antimykotischer Polyenantibiotika und Verfahren zu deren Herstellung | |
| DE3228006C2 (de) | Deoxybouvardin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE2846210A1 (de) | Neue antileukaemische trichothecin epoxide | |
| DE2112430A1 (de) | Pharmazeutische Zubereitung und Verfahren zu ihrer Herstellung | |
| DE2422317A1 (de) | Neue verbindung mit hypolipaemischer wirkung und verfahren zu ihrer herstellung | |
| DE1617601B2 (de) | Arzneimittel zur behandlung der prostatahypertrophie | |
| EP1532129B1 (de) | Sorbicillacton-a-derivate zur behandlung von tumor- und viruserkrankungen | |
| EP0196330B1 (de) | Verwendung von pyrrothinderivaten | |
| DE3808024A1 (de) | 3-(2-halogenalkyl)-1,4-oxathiine und 2-(2-halogenalkyl)-1,4-dithiine und deren verwendung zur behandlung von leukaemie und tumoren | |
| DE2415982B2 (de) | Substituierte 2-(4-chinolylamino)- benzoesaeure-2-(4-phenylpiperazino)-aethylester | |
| DE69922398T2 (de) | Phenantrenderivate mit medizinischer anwendung sowie dessen herstellungsverfahren | |
| DE3544457A1 (de) | Arzneimittel zur behandlung von leberkrankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8141 | Disposal/no request for examination |